There is increased risk for major gastrointestinal bleeding with edoxaban vs VKA therapy in patients with atrial fibrillation following TAVR.

An AI algorithm could help to predict which patients might develop significant heart problems years in advance, just based on ...

The global transcatheter heart valve replacement (TAVR) market is estimated to be valued at USD 8.18 billion in 2025 and is projected to reach USD 32.82 billion by 2035, registering a compound annual ...

Background Current guidelines for aortic valve replacement (AVR) lack consensus on prosthesis selection in middle-aged patients. This study aimed to provide a comprehensive comparison of long-term ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy heart valve system.

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...

The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.

A ViV procedure is required for patients with a life-threatening situation wherein their current bioprosthetic aortic valve is failing due to calcification or structural deterioration, and a new ...

Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve performance and clinical outcomes than those undergoing surgery.

Abstract Background Valve‐in‐valve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines ...

Middle-aged adults who need an aortic valve replacement fare better with mechanical devices than with the valves made from animal tissues that they currently most often receive, U.S. researchers ...